<!DOCTYPE html>
<html><head><meta content="text/html; charset=utf-8" http-equiv="Content-Type"/><base href="https://www.economist.com/middle-east-and-africa/2023/09/17/the-high-tech-low-tech-struggle-to-end-aids"/><style>body{margin-left:0;margin-right:0;margin-top:0}#bN015htcoyT__google-cache-hdr{background:#f8f9fa;font:13px arial,sans-serif;text-align:left;color:#202124;border:0;margin:0;border-bottom:1px solid #dadce0;line-height:16px;padding:16px 28px 24px 28px}#bN015htcoyT__google-cache-hdr *{display:inline;font:inherit;text-align:inherit;color:inherit;line-height:inherit;background:none;border:0;margin:0;padding:0;letter-spacing:0}#bN015htcoyT__google-cache-hdr a{text-decoration:none;color:#1a0dab;}#bN015htcoyT__google-cache-hdr a:hover{text-decoration:underline}#bN015htcoyT__google-cache-hdr a:visited{color:#681da8}#bN015htcoyT__google-cache-hdr div{display:block;margin-top:4px}#bN015htcoyT__google-cache-hdr b{font-weight:bold;display:inline-block;direction:ltr}</style></head><body><div style="position:relative;"><!DOCTYPE html>
<meta charset="utf-8"/><meta content="width=device-width" name="viewport"/><title>The high-tech, low-tech struggle to end AIDS</title><link href="/favicon.ico" rel="icon" type="image/x-icon"/><link href="/engassets/ico/touch-icon-120x120.png" rel="apple-touch-icon"/><link href="/engassets/ico/touch-icon-180x180.png" rel="apple-touch-icon" sizes="180x180"/><link href="/engassets/ico/touch-icon-152x152.png" rel="apple-touch-icon" sizes="152x152"/><link href="/engassets/ico/touch-icon-167x167.png" rel="apple-touch-icon" sizes="167x167"/><link href="/site.webmanifest.json" rel="manifest"/><link href="https://cdn.design-system.economist.com" rel="preconnect"/><link crossorigin="anonymous" href="https://cdn.design-system.economist.com" rel="preconnect"/><link href="https://cdn.parsely.com" rel="preconnect"/><meta content="#E3120B" name="theme-color"/><meta content="#E3120B" name="msapplication-TileColor"/><meta content="/engassets/ico/tile-144.png" name="msapplication-TileImage"/><meta content="The Economist" name="application-name"/><meta content="The Economist" name="msapplication-tooltip"/><link href="https://www.economist.com/middle-east-and-africa/2023/09/17/the-high-tech-low-tech-struggle-to-end-aids" rel="canonical"/><meta content="The virus can be brought under control, but it’s complicated | Middle East &amp; Africa" name="description"/><meta content="frm53mcpva4nold1l3jb8gsn7lcg7fdc" name="parsely-post-id"/><meta content="max-image-preview:large" name="robots"/><meta content="https://www.economist.com/img/b/1280/720/90/media-assets/image/20230916_MAP503.jpg" name="thumbnail"/><meta content="The Economist" property="og:site_name"/><meta content="The high-tech, low-tech struggle to end AIDS" property="og:title"/><meta content="Article" property="og:type"/><meta content="https://www.economist.com/middle-east-and-africa/2023/09/17/the-high-tech-low-tech-struggle-to-end-aids" property="og:url"/><meta content="The virus can be brought under control, but it’s complicated" property="og:description"/><meta content="https://www.economist.com/img/b/1280/720/90/media-assets/image/20230916_MAP503.jpg" property="og:image"/><meta content="@TheEconomist" name="twitter:site"/><meta content="The virus can be brought under control, but it’s complicated" name="twitter:description"/><meta content="summary_large_image" name="twitter:card"/><meta content="https://www.economist.com/img/b/1280/720/90/media-assets/image/20230916_MAP503.jpg" name="twitter:image"/><meta content="193926687345108" property="fb:app_id"/><meta content="6013004059,1487031108050752" property="fb:pages"/><link as="image" fetchpriority="high" imagesizes="(min-width: 960px) 700px, 95vw" imagesrcset="https://www.economist.com/cdn-cgi/image/width=360,quality=80,format=auto/content-assets/images/20230916_MAP503.jpg 360w, https://www.economist.com/cdn-cgi/image/width=384,quality=80,format=auto/content-assets/images/20230916_MAP503.jpg 384w, https://www.economist.com/cdn-cgi/image/width=480,quality=80,format=auto/content-assets/images/20230916_MAP503.jpg 480w, https://www.economist.com/cdn-cgi/image/width=600,quality=80,format=auto/content-assets/images/20230916_MAP503.jpg 600w, https://www.economist.com/cdn-cgi/image/width=834,quality=80,format=auto/content-assets/images/20230916_MAP503.jpg 834w, https://www.economist.com/cdn-cgi/image/width=960,quality=80,format=auto/content-assets/images/20230916_MAP503.jpg 960w, https://www.economist.com/cdn-cgi/image/width=1096,quality=80,format=auto/content-assets/images/20230916_MAP503.jpg 1096w, https://www.economist.com/cdn-cgi/image/width=1280,quality=80,format=auto/content-assets/images/20230916_MAP503.jpg 1280w, https://www.economist.com/cdn-cgi/image/width=1424,quality=80,format=auto/content-assets/images/20230916_MAP503.jpg 1424w" rel="preload"/><meta content="37" name="next-head-count"/><link as="style" href="/engassets/_next/static/css/350f9adc4faf580e.css" rel="preload"/><link data-n-g="" href="/engassets/_next/static/css/350f9adc4faf580e.css" rel="stylesheet"/><link as="style" href="/engassets/_next/static/css/aea4c7b56d071fa0.css" rel="preload"/><link data-n-p="" href="/engassets/_next/static/css/aea4c7b56d071fa0.css" rel="stylesheet"/><noscript data-n-css=""></noscript><div id="__next"><div><style data-emotion="css-global vbm3ru">body{color:var(--ds-color-london-5);font-family:var(--ds-type-system-serif);font-size:var(--ds-type-scale-0);font-style:normal;font-weight:400;line-height:var(--ds-type-leading-lower);-webkit-text-size-adjust:100%;}img{height:auto;max-width:100%;}.visually-hidden{clip:rect(0.0625rem,0.0625rem,0.0625rem,0.0625rem);height:0.0625rem;margin:-0.0625rem;overflow:hidden;padding:0;position:absolute;width:0.0625rem;}</style><style data-emotion="css-global 1s3sepm">.advert >div{display:inline-block;margin:0.75rem 0 0;}.advert--aside{grid-column:1/-1;margin:0;}.advert--inline{border:0.0625rem solid hsla(var(--ds-color-hsl-london-85),0.5);box-shadow:none;margin-bottom:2.1875rem;margin-top:1.3125rem;}.advert--regwall{border:0.0625rem solid hsla(var(--ds-color-hsl-london-85),0.5);box-shadow:none;margin-bottom:0;margin-top:2.25rem;}.advert--leaderboard{display:none;}.advert--billboard{display:none;}.advert--full-width{margin:0 0 3rem 0;}.advert.hidden{margin:0;}@media (min-width: 60rem){.advert--leaderboard{display:block;height:9.8125rem;}.advert--full-width{margin-bottom:3.5rem;}}@media (max-width: 79.9375rem){.advert--right-rail,.layout-rhr-lower{display:none;}}@media (min-width: 80rem){.advert--right-rail{grid-area:1/9/3/-1;height:40.9375rem;}.advert--right-rail .advert{box-shadow:none;}}@media (min-width: 89rem){.advert--right-rail{grid-column-start:10;}}</style><style data-emotion="css-global kp70i8">#piano-ribbon{position:fixed;width:100%;z-index:96;}#piano-ribbon.show{bottom:0;}.tp-backdrop{background-color:hsla(var(--ds-color-hsl-london-5),0.6);left:0;position:fixed;top:0;width:100%;}.tp-backdrop.closed{display:none;}.tp-modal{left:50%;position:fixed;top:8rem;-webkit-transform:translate(-50%,0);-moz-transform:translate(-50%,0);-ms-transform:translate(-50%,0);transform:translate(-50%,0);width:100%!important;}@media (min-width:22.5rem){.tp-modal{top:50%;-webkit-transform:translate(-50%,-50%);-moz-transform:translate(-50%,-50%);-ms-transform:translate(-50%,-50%);transform:translate(-50%,-50%);}}.tp-modal.closed{display:none!important;}.tp-iframe-wrapper{max-width:100%!important;width:100%!important;}.tp-modal iframe{width:100%!important;}</style><div class="global-layout css-0 e1xjmggb0"><div id="piano-app-banner"></div><style data-emotion="css ecmw3n">.css-ecmw3n{background-color:var(--ds-color-london-100);position:absolute;}.css-ecmw3n,.css-ecmw3n .ds-masthead{width:100%;}.css-ecmw3n .ds-masthead.is-open,.css-ecmw3n .ds-masthead.account-is-open,.css-ecmw3n .ds-masthead.search-is-open{position:fixed;z-index:98;}.css-ecmw3n +div,.css-ecmw3n +div+footer{position:relative;top:7.25rem;}@media (max-width: 37.4375rem){.css-ecmw3n .ds-masthead.is-open,.css-ecmw3n .ds-masthead.search-is-open{overflow-y:scroll;}.css-ecmw3n .ds-masthead.account-is-open{overflow-y:scroll;height:100%;}.css-ecmw3n .ds-masthead.is-open{height:100%;}.css-ecmw3n .ds-masthead.is-open::after{background:var(--ds-color-london-20);bottom:-50vh;content:'';height:100vh;position:fixed;width:100%;z-index:-1;}.css-ecmw3n .ds-masthead +div,.css-ecmw3n .ds-masthead +div+footer{top:7.25rem;}}@media (min-width: 22.5rem){.css-ecmw3n .ds-masthead{margin-bottom:1rem;}.css-ecmw3n .ds-masthead.is-open{height:100%;}.css-ecmw3n .ds-masthead +div,.css-ecmw3n .ds-masthead +div+footer{top:7.25rem;}}@media (min-width: 37.5rem){.css-ecmw3n .ds-masthead{margin-bottom:0.5rem;}.css-ecmw3n .ds-masthead.is-open,.css-ecmw3n .ds-masthead.account-is-open,.css-ecmw3n .ds-masthead.search-is-open{height:auto;position:absolute;}.css-ecmw3n +div,.css-ecmw3n +div+footer{top:7.25rem;}}@media (min-width: 60rem){.css-ecmw3n +div,.css-ecmw3n +div+footer{top:8.5rem;}}@media (max-width: 19.5625rem){.css-ecmw3n +div,.css-ecmw3n +div+footer{top:10.5rem;}}</style><div><style data-emotion="css 9rt3sc">.css-9rt3sc{background-color:inherit;margin-bottom:7rem;}</style><div class="css-9rt3sc e10tor440"><main id="content" role="main"><article data-test-id="NewArticle" id="new-article-template"><style data-emotion="css 1bfdg3q">.css-1bfdg3q{margin-left:auto;margin-right:auto;max-width:89.5rem;position:relative;padding-left:var(--ds-grid-gap);padding-right:var(--ds-grid-gap);}@media (min-width: 37.5rem){.css-1bfdg3q{padding-left:var(--ds-grid-gutter);padding-right:var(--ds-grid-gutter);}}</style><div class="css-1bfdg3q e1pkqesp0" data-test-id="standard-article-template"><style data-emotion="css 1qjp74c">.css-1qjp74c{display:grid;grid-auto-flow:row;grid-column-gap:var(--ds-grid-gutter);grid-row-gap:3rem;grid-row-gap:0;grid-auto-columns:1fr;margin-left:auto;margin-right:auto;max-width:89.5rem;overflow:visible;position:relative;}@media (min-width: 22.5rem){.css-1qjp74c{grid-template:auto/repeat(6, minmax(0, 1fr));}}@media (min-width: 52.125rem){.css-1qjp74c{grid-template:auto/repeat(9, minmax(0, 1fr));}}@media (min-width: 80rem){.css-1qjp74c{grid-template:auto/repeat(12, minmax(0, 1fr));}}@media (min-width: 89rem){.css-1qjp74c{grid-template:auto/repeat(16, minmax(0, 1fr));}}</style><div class="css-1qjp74c e8tkvfk0"><style data-emotion="css 1r2sn2n">.css-1r2sn2n{position:relative;}@media (min-width: 22.5rem){.css-1r2sn2n{grid-column-start:1;}}@media (min-width: 52.125rem){.css-1r2sn2n{grid-column-start:2;}}@media (min-width: 68.5rem){.css-1r2sn2n{grid-column-start:3;}}@media (min-width: 80rem){.css-1r2sn2n{grid-column-start:3;}}@media (min-width: 89rem){.css-1r2sn2n{grid-column-start:4;}}@media (min-width: 22.5rem){.css-1r2sn2n{grid-column-end:7;}}@media (min-width: 52.125rem){.css-1r2sn2n{grid-column-end:9;}}@media (min-width: 68.5rem){.css-1r2sn2n{grid-column-end:8;}}@media (min-width: 80rem){.css-1r2sn2n{grid-column-end:9;}}@media (min-width: 89rem){.css-1r2sn2n{grid-column-end:12;}}.css-1r2sn2n:last-child::after{height:0;}</style><div class="css-1r2sn2n e1mdktgm0"><style data-emotion="css qm1vln">.css-qm1vln .elmr55g0{margin-top:0.75rem;}@media (min-width: 37.5rem){.css-qm1vln .elmr55g0{margin-top:1rem;}}@media (min-width: 60rem){.css-qm1vln .elmr55g0{margin-top:1.25rem;}}</style><section class="css-qm1vln e1m3q8rc0"><style data-emotion="css b4a1pi">.css-b4a1pi{margin-bottom:0.25rem;white-space:pre-wrap;}@media (min-width: 37.5rem){.css-b4a1pi{margin-bottom:0.5rem;}}</style><div class="css-b4a1pi erjyvvd0"><style data-emotion="css 1te5c83">.css-1te5c83{color:var(--ds-color-economist-red);font-family:var(--ds-type-system-sans);font-size:var(--ds-type-scale--1);font-weight:400;line-height:var(--ds-type-leading-lower);}.css-1te5c83 a{-webkit-text-decoration:none;text-decoration:none;color:inherit;-webkit-transition:color var(--ds-interactions-transition);transition:color var(--ds-interactions-transition);outline:solid transparent;}.css-1te5c83 a:hover,.css-1te5c83 a:active{color:var(--ds-color-chicago-30);}.css-1te5c83 a:hover span{-webkit-text-decoration:underline;text-decoration:underline;}.css-1te5c83 a:focus{color:var(--ds-color-london-10);background-color:var(--ds-color-chicago-95);}</style><span class="css-1te5c83 e1cjb9as0"><a data-analytics="sidebar:section" href="/middle-east-and-africa/"><span>Middle East and Africa</span></a></span><style data-emotion="css 1mdqtqm">.css-1mdqtqm{font-family:var(--ds-type-system-sans);font-size:var(--ds-type-scale--1);font-weight:400;line-height:var(--ds-type-leading-lower);color:var(--header-fly-color, var(--ds-color-london-10));}</style><span class="css-1mdqtqm e11bnqe00"> | <!-- -->Making sex safer again</span></div><style data-emotion="css fk78xg">.css-fk78xg{color:var(--header-headline-color, var(--ds-color-london-10));font-family:var(--ds-type-system-serif);font-size:var(--ds-type-scale-6);font-weight:400;line-height:var(--ds-type-leading-upper);}@media (min-width: 37.5rem){.css-fk78xg{font-size:var(--ds-type-scale-8);line-height:var(--ds-type-leading-upper);}}@media (min-width: 60rem){.css-fk78xg{font-size:var(--ds-type-scale-9);line-height:var(--ds-type-leading-upper);}}</style><h1 class="css-fk78xg e1t4u3eq0">The high-tech, low-tech struggle to end AIDS</h1><style data-emotion="css o55d57">.css-o55d57{color:var(--header-rubric-color, var(--ds-color-london-10));font-family:var(--ds-type-system-serif);font-size:var(--ds-type-scale-2);font-style:normal;font-weight:400;line-height:var(--ds-type-leading-lower);}</style><h2 class="css-o55d57 elmr55g0">The virus can be brought under control, but it’s complicated</h2></section></div><style data-emotion="css kpd7oo">.css-kpd7oo{position:relative;}@media (min-width: 22.5rem){.css-kpd7oo{grid-column-start:1;}}@media (min-width: 52.125rem){.css-kpd7oo{grid-column-start:1;}}@media (min-width: 68.5rem){.css-kpd7oo{grid-column-start:2;}}@media (min-width: 80rem){.css-kpd7oo{grid-column-start:3;}}@media (min-width: 89rem){.css-kpd7oo{grid-column-start:4;}}@media (min-width: 22.5rem){.css-kpd7oo{grid-column-end:7;}}@media (min-width: 52.125rem){.css-kpd7oo{grid-column-end:10;}}@media (min-width: 68.5rem){.css-kpd7oo{grid-column-end:9;}}@media (min-width: 80rem){.css-kpd7oo{grid-column-end:9;}}@media (min-width: 89rem){.css-kpd7oo{grid-column-end:12;}}.css-kpd7oo:last-child::after{height:0;}</style><div class="css-kpd7oo e1mdktgm0"><style data-emotion="css 1ugvd2u">.css-1ugvd2u{margin-top:2.5rem;}.css-1ugvd2u img{width:100%;}@media (min-width: 60rem){.css-1ugvd2u{margin-top:3rem;}}</style><section class="css-1ugvd2u e18wk22u0"><style data-emotion="css qts40t">.css-qts40t img{display:block;}.css-qts40t .edweubf2{margin-top:0.25rem;}</style><figure class="css-qts40t e1197rjj0"><img alt="A lab technician draws blood from a patient for HIV testing" data-nimg="1" decoding="async" fetchpriority="high" height="720" sizes="(min-width: 960px) 700px, 95vw" src="https://www.economist.com/cdn-cgi/image/width=1424,quality=80,format=auto/content-assets/images/20230916_MAP503.jpg" srcset="https://www.economist.com/cdn-cgi/image/width=360,quality=80,format=auto/content-assets/images/20230916_MAP503.jpg 360w, https://www.economist.com/cdn-cgi/image/width=384,quality=80,format=auto/content-assets/images/20230916_MAP503.jpg 384w, https://www.economist.com/cdn-cgi/image/width=480,quality=80,format=auto/content-assets/images/20230916_MAP503.jpg 480w, https://www.economist.com/cdn-cgi/image/width=600,quality=80,format=auto/content-assets/images/20230916_MAP503.jpg 600w, https://www.economist.com/cdn-cgi/image/width=834,quality=80,format=auto/content-assets/images/20230916_MAP503.jpg 834w, https://www.economist.com/cdn-cgi/image/width=960,quality=80,format=auto/content-assets/images/20230916_MAP503.jpg 960w, https://www.economist.com/cdn-cgi/image/width=1096,quality=80,format=auto/content-assets/images/20230916_MAP503.jpg 1096w, https://www.economist.com/cdn-cgi/image/width=1280,quality=80,format=auto/content-assets/images/20230916_MAP503.jpg 1280w, https://www.economist.com/cdn-cgi/image/width=1424,quality=80,format=auto/content-assets/images/20230916_MAP503.jpg 1424w" style="color:transparent" width="1280"/><style data-emotion="css 18w36g1">.css-18w36g1{width:100%;font-family:var(--ds-type-system-sans);}</style><figcaption class="css-18w36g1 edweubf2"><style data-emotion="css 6pzdis">.css-6pzdis{font-family:var(--ds-type-system-sans-smallcaps);font-size:var(--ds-type-scale--1);font-weight:400;font-variant-ligatures:none;line-height:var(--ds-type-leading-lower);text-transform:lowercase;color:var(--ds-color-london-35);}.edweubf0+.css-6pzdis{margin-left:0.5rem;}</style><span class="css-6pzdis edweubf1">image: Getty Images</span></figcaption></figure></section></div><div class="css-1r2sn2n e1mdktgm0"><style data-emotion="css 17yzdrv">.css-17yzdrv .e8htone0{margin-bottom:1.75rem;padding-top:1.75rem;border-top:0.0625rem solid var(--ds-color-london-85);}.css-17yzdrv .e1hqvufh0{padding:1.25rem 0;border-top:0.0625rem solid var(--ds-color-london-85);display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;-webkit-box-pack:center;-ms-flex-pack:center;-webkit-justify-content:center;justify-content:center;-webkit-align-items:center;-webkit-box-align:center;-ms-flex-align:center;align-items:center;}.css-17yzdrv .e1hqvufh0 +.e1a395ds0{margin-top:0;}</style><div class="css-17yzdrv euxoahl0"><style data-emotion="css 1fiks87">.css-1fiks87{margin-top:0.25rem;}.css-1fiks87 +.ev2vbd30{margin-top:0.75rem;}@media (min-width: 37.5rem){.css-1fiks87 +.ev2vbd30{margin-top:1.75rem;}}@media (min-width: 80rem){.css-1fiks87{margin-top:0.25rem;}}</style><div class="css-1fiks87 e1rnrkkh0"><style data-emotion="css 19diqro">.css-19diqro{position:relative;border-bottom:0;color:var(--ds-color-london-70);}@media (min-width: 37.5rem){.css-19diqro{border-bottom:0.0625rem solid var(--ds-color-london-85);}}.css-19diqro .ds-actioned-link{margin-right:0.625rem;}@media (min-width: 37.5rem){.css-19diqro .ds-actioned-link{margin-left:0.625rem;margin-right:0;}}.css-19diqro .ei4w8y0{margin-right:0.625rem;margin-top:0;}@media (min-width: 37.5rem){.css-19diqro .ei4w8y0{margin-right:0;}}.css-19diqro .ei4w8y0 .ds-actioned-link{margin-right:0;}.css-19diqro >.eygoqsu0>*{padding:1rem 0;}.css-19diqro >.eygoqsu0>*:nth-of-type(2){border-top:0.0625rem solid var(--ds-color-london-85);}@media (min-width: 37.5rem){.css-19diqro >.eygoqsu0>*:nth-of-type(2){border-top:0;}}</style><div class="css-19diqro e1f4i2e00"><style data-emotion="css w0h03k">.css-w0h03k{display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;-webkit-flex-direction:column;-ms-flex-direction:column;flex-direction:column;-webkit-align-items:stretch;-webkit-box-align:stretch;-ms-flex-align:stretch;align-items:stretch;-webkit-box-pack:start;-ms-flex-pack:start;-webkit-justify-content:flex-start;justify-content:flex-start;}@media (min-width: 37.5rem){.css-w0h03k{-webkit-flex-direction:row;-ms-flex-direction:row;flex-direction:row;}}@media (min-width: 37.5rem){.css-w0h03k{-webkit-align-items:center;-webkit-box-align:center;-ms-flex-align:center;align-items:center;}}@media (min-width: 37.5rem){.css-w0h03k{-webkit-box-pack:justify;-webkit-justify-content:space-between;justify-content:space-between;}}</style><div class="css-w0h03k eygoqsu0"><div><style data-emotion="css j5ehde">.css-j5ehde{font-size:var(--ds-type-scale--1);font-family:var(--ds-type-system-sans);font-weight:400;line-height:var(--ds-type-leading-lower);color:var(--ds-color-london-35);}</style><time class="css-j5ehde exy50qi0" datetime="2023-09-17T23:14:25.487Z"> <!-- -->Sep 17th 2023</time> | <style data-emotion="css 1a0w51d">.css-1a0w51d{font-size:var(--ds-type-scale--2);font-family:var(--ds-type-system-sans);font-weight:400;line-height:var(--ds-type-leading-lower);letter-spacing:0.0325rem;text-transform:uppercase;color:var(--ds-color-london-35);}</style><span class="css-1a0w51d e1p34r340">JOHANNESBURG</span></div><div><style data-emotion="css 1902i5q">.css-1902i5q{display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;}</style></div></div></div></div><style data-emotion="css 12k3cm0">.css-12k3cm0{margin-top:0.75rem;margin-bottom:0.875rem;display:inline-block;}@media (min-width: 37.5rem){.css-12k3cm0{margin-top:1.75rem;}}.css-12k3cm0 .e4on4sn0{position:relative;}</style><section class="css-12k3cm0 e116ty901" data-body-id="cp2"><style data-emotion="css 1tl6jh1">.css-1tl6jh1 *+*{margin-top:0.875rem;}.css-1tl6jh1 .e195f1ec0{margin-top:0;}.css-1tl6jh1 .e50l3u40{margin:0;}.css-1tl6jh1 .e50l3u40 +*{margin-top:2.1875rem;}.css-1tl6jh1 .e50l3u40 .e50l3u41{margin-top:0;}.css-1tl6jh1 .eqtgzhl0+*{margin-top:1.75rem;}.css-1tl6jh1 *+.eqtgzhl0{margin-top:1.75rem;}.css-1tl6jh1 *+.e1r78fak0{margin-top:1.75rem;}.css-1tl6jh1 .e1r78fak0+*{margin-top:1.75rem;}.css-1tl6jh1 *+.e10jdj00{margin-top:1.3125rem;}.css-1tl6jh1 *+.e1m2w0l00{margin-top:2.1875rem;}.css-1tl6jh1 .e1m2w0l00+*{margin-top:2.1875rem;}.css-1tl6jh1 .e1m2w0l00+.e195f1ec0{margin-top:2.1875rem;}.css-1tl6jh1 .e195f1ec0+.e1m2w0l00{margin-top:2.1875rem;}.css-1tl6jh1 >.e8f47sz0+*{margin-top:0;}.css-1tl6jh1 .e1xfd4x10+*{margin-top:1.3125rem;}.css-1tl6jh1 >.e69v9ey0+*{margin-top:1.3125rem;}.css-1tl6jh1 .e10jdj00+.e190yofl0{margin-top:1.3125rem;}.css-1tl6jh1 .e69v9ey0+.e1r78fak0{margin-top:1.3125rem;}.css-1tl6jh1 .e69v9ey0+.eqtgzhl0{margin-top:1.3125rem;}.css-1tl6jh1 .e1m2w0l00+.e1m2w0l00{margin-top:1.3125rem;}.css-1tl6jh1 .e10jdj00+.e69v9ey0{margin-top:1.3125rem;}.css-1tl6jh1 .e8f47sz0+.e69v9ey0{margin-top:0.875rem;}.css-1tl6jh1 .eitqf4z0+*,.css-1tl6jh1 .e195f1ec0+*{margin-top:2.1875rem;}.css-1tl6jh1 *+.eitqf4z0,.css-1tl6jh1 *+.e195f1ec0{margin-top:2.1875rem;}.css-1tl6jh1 .eitqf4z0+.eitqf4z0,.css-1tl6jh1 .e195f1ec0+.e195f1ec0,.css-1tl6jh1 .eitqf4z0+.e195f1ec0,.css-1tl6jh1 .e195f1ec0+.eitqf4z0{margin-top:1.3125rem;}@media (min-width: 37.5rem){.css-1tl6jh1 .eitqf4z1{margin-bottom:0.875rem;}}.css-1tl6jh1 .e10jdj00+.eitqf4z1{margin-top:1.3125rem;}.css-1tl6jh1 .e10jdj00+.eitqf4z1+.e190yofl0{margin-top:1.3125rem;}.css-1tl6jh1 .e1m2w0l00+.eitqf4z1+.e190yofl0{margin-top:2.1875rem;}.css-1tl6jh1 .eitqf4z1+.e190yofl0+.e69v9ey0{margin-top:1.3125rem;}.css-1tl6jh1 .e1r78fak0+.eitqf4z1,.css-1tl6jh1 .e1r78fak0+.eitqf4z1+.e190yofl0,.css-1tl6jh1 .eqtgzhl0+.eitqf4z1+.e190yofl0,.css-1tl6jh1 .eqtgzhl0+.eitqf4z1{margin-top:2.1875rem;}.css-1tl6jh1 .e190yofl0+.eitqf4z1,.css-1tl6jh1 .e190yofl0+.eitqf4z1+.e190yofl0,.css-1tl6jh1 .e69v9ey0+.eitqf4z1,.css-1tl6jh1 .e69v9ey0+.eitqf4z1+.e190yofl0{margin-top:1.3125rem;}@media (max-width: 37.4375rem){.css-1tl6jh1 .eitqf4z1+.e190yofl0,.css-1tl6jh1 .eqtgzhl0+.eitqf4z1+.e190yofl0,.css-1tl6jh1 .e1r78fak0+.eitqf4z1+.e190yofl0{margin-top:0.875rem;}}.css-1tl6jh1 .eitqf4z1+*:not(.e190yofl0),.css-1tl6jh1 .eitqf4z1+.e190yofl0+*:not(.e190yofl0){clear:both;}.css-1tl6jh1 .e1cbnkh80{clear:both;}.css-1tl6jh1 *+.e1cbnkh80{margin-top:2.1875rem;}.css-1tl6jh1 .e1cbnkh80+*{margin-top:2.1875rem;}</style><div class="css-1tl6jh1 e116ty902"><style data-emotion="css 1hno3qs">.css-1hno3qs{color:var(--ds-color-london-5);font-family:var(--ds-type-system-serif);font-weight:400;font-size:var(--ds-type-scale-2);line-height:var(--ds-type-leading-lower);}.css-1hno3qs del,.css-1hno3qs s{-webkit-text-decoration:strikethrough;text-decoration:strikethrough;}.css-1hno3qs strong,.css-1hno3qs b{font-weight:700;}.css-1hno3qs em,.css-1hno3qs i{font-style:italic;}.css-1hno3qs sup{bottom:0.5rem;font-size:smaller;position:relative;vertical-align:baseline;}.css-1hno3qs sub{font-size:smaller;position:relative;top:0.25rem;vertical-align:baseline;}.css-1hno3qs small,.css-1hno3qs .small-caps{display:inline;font-family:var(--ds-type-system-serif-smallcaps);font-size:inherit;font-variant-ligatures:none;font-weight:400;line-height:var(--ds-type-leading-lower);text-transform:lowercase;}.css-1hno3qs u,.css-1hno3qs .underline{-webkit-text-decoration:underline;text-decoration:underline;text-underline-offset:0.125rem;text-decoration-thickness:0.0625rem;}.css-1hno3qs a{color:var(--ds-color-london-5);-webkit-text-decoration:underline;text-decoration:underline;text-decoration-color:var(--ds-color-chicago-45);text-decoration-thickness:0.125rem;text-underline-offset:0.125rem;}.css-1hno3qs a:hover{color:var(--ds-color-chicago-30);-webkit-text-decoration:underline;text-decoration:underline;text-decoration-thickness:0.0625rem;}.css-1hno3qs a:focus{background-color:var(--ds-color-chicago-95);color:var(--ds-color-london-5);outline:none;-webkit-text-decoration:underline;text-decoration:underline;text-decoration-color:var(--ds-color-chicago-45);text-decoration-thickness:0.125rem;}.css-1hno3qs a:active{background-color:var(--ds-color-chicago-95);color:var(--ds-color-london-5);-webkit-text-decoration:none;text-decoration:none;}.css-1hno3qs [data-caps='initial'],.css-1hno3qs .drop-cap{float:left;font-size:3.3125rem;height:3.125rem;line-height:1;margin:-0.0625rem 0.2rem 0 0;text-transform:uppercase;}@media (min-width: 22.5rem){.css-1hno3qs [data-caps='initial'],.css-1hno3qs .drop-cap{font-size:3.8125rem;height:3.375rem;}}.css-1hno3qs [data-ornament='ufinish'],.css-1hno3qs .ufinish{font-size:0;}.css-1hno3qs [data-ornament='ufinish']::after,.css-1hno3qs .ufinish::after{font-family:var(--ds-type-system-symbols);font-size:var(--ds-type-scale-1);content:'7';color:var(--ds-color-economist-red);}@media (min-width: 22.5rem){.css-1hno3qs [data-ornament='ufinish']::after,.css-1hno3qs .ufinish::after{font-size:var(--ds-type-scale-2);}}</style><p class="css-1hno3qs e190yofl0" data-component="paragraph"><span data-caps="initial">H</span><small>ow can</small> cotton wool help in the fight against <small>AIDS</small>? The answer is surprising, and illuminates how complicated it will be to beat <a href="https://www.economist.com/leaders/2022/08/03/do-not-let-hiv-and-aids-slide-down-the-priority-list">the deadliest sexually transmitted sickness</a> of all time. The struggle involves not only dazzling science but also old-fashioned insights into human behaviour, rational and irrational.</p><p class="css-1hno3qs e190yofl0" data-component="paragraph">Many people who do not have <small>HIV</small>, the virus that causes <small>AIDS</small>, know they are at risk. They can take pre-exposure prophylaxis (<small>P</small>r<small>EP</small>), a kind of drug that reduces their chance of contracting it by 99% or so. This comes as a daily pill, and is popular among gay men in rich countries.</p><p class="css-1hno3qs e190yofl0" data-component="paragraph">However, there is a much larger group of people at high risk, for whom a daily pill is far from ideal: heterosexual women in poor places where <small>HIV</small> is still very common. If their boyfriends discover they are taking the pill, they may conclude that their girlfriend does not trust them, or that she is planning to cheat on them. And a depressing number of boyfriends who suspect such things react violently.</p><style data-emotion="css 1bzwzkr">.css-1bzwzkr{width:21rem;margin-left:auto;margin-right:auto;}@media (min-width: 37.5rem){.css-1bzwzkr{float:left;margin-right:var(--ds-grid-gutter);}}</style><div class="css-1bzwzkr eitqf4z1"><figure class="css-qts40t e1197rjj0"><img alt="" data-nimg="1" decoding="async" height="663" loading="lazy" sizes="300px" src="https://www.economist.com/cdn-cgi/image/width=1424,quality=80,format=auto/content-assets/images/20230923_MAM941.png" srcset="https://www.economist.com/cdn-cgi/image/width=16,quality=80,format=auto/content-assets/images/20230923_MAM941.png 16w, https://www.economist.com/cdn-cgi/image/width=32,quality=80,format=auto/content-assets/images/20230923_MAM941.png 32w, https://www.economist.com/cdn-cgi/image/width=48,quality=80,format=auto/content-assets/images/20230923_MAM941.png 48w, https://www.economist.com/cdn-cgi/image/width=64,quality=80,format=auto/content-assets/images/20230923_MAM941.png 64w, https://www.economist.com/cdn-cgi/image/width=96,quality=80,format=auto/content-assets/images/20230923_MAM941.png 96w, https://www.economist.com/cdn-cgi/image/width=128,quality=80,format=auto/content-assets/images/20230923_MAM941.png 128w, https://www.economist.com/cdn-cgi/image/width=256,quality=80,format=auto/content-assets/images/20230923_MAM941.png 256w, https://www.economist.com/cdn-cgi/image/width=360,quality=80,format=auto/content-assets/images/20230923_MAM941.png 360w, https://www.economist.com/cdn-cgi/image/width=384,quality=80,format=auto/content-assets/images/20230923_MAM941.png 384w, https://www.economist.com/cdn-cgi/image/width=480,quality=80,format=auto/content-assets/images/20230923_MAM941.png 480w, https://www.economist.com/cdn-cgi/image/width=600,quality=80,format=auto/content-assets/images/20230923_MAM941.png 600w, https://www.economist.com/cdn-cgi/image/width=834,quality=80,format=auto/content-assets/images/20230923_MAM941.png 834w, https://www.economist.com/cdn-cgi/image/width=960,quality=80,format=auto/content-assets/images/20230923_MAM941.png 960w, https://www.economist.com/cdn-cgi/image/width=1096,quality=80,format=auto/content-assets/images/20230923_MAM941.png 1096w, https://www.economist.com/cdn-cgi/image/width=1280,quality=80,format=auto/content-assets/images/20230923_MAM941.png 1280w, https://www.economist.com/cdn-cgi/image/width=1424,quality=80,format=auto/content-assets/images/20230923_MAM941.png 1424w" style="color:transparent" width="608"/><figcaption class="css-18w36g1 edweubf2"><span class="css-6pzdis edweubf1">image: The Economist</span></figcaption></figure></div><p class="css-1hno3qs e190yofl0" data-component="paragraph"><a href="https://www.economist.com/by-invitation/2023/09/15/bjorn-lomborg-calls-for-a-new-approach-to-meeting-global-development-goals">A high-tech solution</a> is on the horizon: cabotegravir, from ViiV healthcare, a single injection that lasts for two months and is much more discreet than a daily pill. Alas, it is new, costly and not yet widely available, especially in Africa, where the virus is most widespread. So Patrick Mdletshe of the KwaZulu Natal Provincial Council on <small>AIDS</small> in South Africa offers a low-tech fix: stuff cotton wool in the bottle so the daily pills don’t rattle and your boyfriend won’t notice that you are taking them.</p><p class="css-1hno3qs e190yofl0" data-component="paragraph"><small>UNAIDS</small>, a <small>UN</small> body, hopes to end <small>AIDS</small> as a major public-health threat by 2030, building on the staggering success of the past two decades. <small>AIDS</small>, which weakens the immune system, has killed about 40m people—more than covid-19. However, the pace at which people are dying of it has fallen dramatically. In the early 2000s it was 2m a year, largely in poor countries, where hardly anyone could afford $10,000 a year for life-prolonging pills. In some African countries between a fifth and quarter of the adult population was infected with <small>HIV</small>; nearly all were expected to die of it. Life expectancy in Zimbabwe and Eswatini fell by two decades.</p><div class="adComponent_advert__V79Pp adComponent_incontent__Bxd2J adComponent_hidden___o_ZB css-0 e1cbnkh80"><div><div class="adComponent_adcontainer__dO1Zm" id="econ-1"></div></div></div><p class="css-1hno3qs e190yofl0" data-component="paragraph"><small>AIDS</small> slaughtered adults in their productive prime—slowly. Breadwinners sickened, stopped earning and needed care. Their spouses looked after them until they, too, fell ill. Daughters dropped out of school to care for ailing parents. Families were plunged into penury.</p><p class="css-1hno3qs e190yofl0" data-component="paragraph">Then the price of antiretroviral pills plummeted, as drug firms offered steep discounts for poor countries and donors chipped in billions to pay for them. Today a year’s supply can cost a mere $45. Between 2001 and 2019 life expectancy in sub-Saharan Africa rose by 17%—and much more in the worst-affected countries (see chart). Globally, some 21m deaths have been averted, by one estimate. Today, three-quarters of those infected—roughly 30m people—are receiving treatment.</p><div class="css-1bzwzkr eitqf4z1"><figure class="css-qts40t e1197rjj0"><img alt="" data-nimg="1" decoding="async" height="662" loading="lazy" sizes="300px" src="https://www.economist.com/cdn-cgi/image/width=1424,quality=80,format=auto/content-assets/images/20230923_MAC620.png" srcset="https://www.economist.com/cdn-cgi/image/width=16,quality=80,format=auto/content-assets/images/20230923_MAC620.png 16w, https://www.economist.com/cdn-cgi/image/width=32,quality=80,format=auto/content-assets/images/20230923_MAC620.png 32w, https://www.economist.com/cdn-cgi/image/width=48,quality=80,format=auto/content-assets/images/20230923_MAC620.png 48w, https://www.economist.com/cdn-cgi/image/width=64,quality=80,format=auto/content-assets/images/20230923_MAC620.png 64w, https://www.economist.com/cdn-cgi/image/width=96,quality=80,format=auto/content-assets/images/20230923_MAC620.png 96w, https://www.economist.com/cdn-cgi/image/width=128,quality=80,format=auto/content-assets/images/20230923_MAC620.png 128w, https://www.economist.com/cdn-cgi/image/width=256,quality=80,format=auto/content-assets/images/20230923_MAC620.png 256w, https://www.economist.com/cdn-cgi/image/width=360,quality=80,format=auto/content-assets/images/20230923_MAC620.png 360w, https://www.economist.com/cdn-cgi/image/width=384,quality=80,format=auto/content-assets/images/20230923_MAC620.png 384w, https://www.economist.com/cdn-cgi/image/width=480,quality=80,format=auto/content-assets/images/20230923_MAC620.png 480w, https://www.economist.com/cdn-cgi/image/width=600,quality=80,format=auto/content-assets/images/20230923_MAC620.png 600w, https://www.economist.com/cdn-cgi/image/width=834,quality=80,format=auto/content-assets/images/20230923_MAC620.png 834w, https://www.economist.com/cdn-cgi/image/width=960,quality=80,format=auto/content-assets/images/20230923_MAC620.png 960w, https://www.economist.com/cdn-cgi/image/width=1096,quality=80,format=auto/content-assets/images/20230923_MAC620.png 1096w, https://www.economist.com/cdn-cgi/image/width=1280,quality=80,format=auto/content-assets/images/20230923_MAC620.png 1280w, https://www.economist.com/cdn-cgi/image/width=1424,quality=80,format=auto/content-assets/images/20230923_MAC620.png 1424w" style="color:transparent" width="608"/><figcaption class="css-18w36g1 edweubf2"><span class="css-6pzdis edweubf1">image: The Economist</span></figcaption></figure></div><p class="css-1hno3qs e190yofl0" data-component="paragraph">Unfortunately, triumph has bred complacency, argues Peter Sands, the head of the Global Fund to Fight <small>AIDS</small>, Tuberculosis and Malaria, a donor-financed body. “There’s a diminishing sense of urgency,” he says. Or worse. The biggest donor by far is America. Its global <small>AIDS</small> programme, <small>PEPFAR</small>, which was set up by President George W. Bush, expires on September 30th and some Republicans are trying to block its reauthorisation. A recent report from a conservative think-tank called <small>AIDS</small> “primarily a lifestyle disease” and griped that <small>PEPFAR</small> was being used to promote a “radical social agenda overseas”. (It does not bar aid recipients from talking about abortion.) Mr Bush is horrified. “To abandon our commitment now would forfeit two decades of unimaginable progress and raise further questions about the worth of America’s word,” he fumed in the <i>Washington Post</i> on September 13th.</p><div class="adComponent_advert__V79Pp adComponent_incontent__Bxd2J adComponent_hidden___o_ZB css-0 e1cbnkh80"><div><div class="adComponent_adcontainer__dO1Zm" id="econ-2"></div></div></div><p class="css-1hno3qs e190yofl0" data-component="paragraph">An estimated 39m people are <small>HIV</small> positive—more than half of them in Africa. All will need lifelong treatment, unless a cure is found. Meanwhile, the virus is still spreading. Some 1.3m people were freshly infected last year. In Eastern Europe and the Middle East, the numbers of new infections in 2022 were 49% and 61% higher than in 2010, albeit from low bases.</p><p class="css-1hno3qs e190yofl0" data-component="paragraph">There are two main approaches to tackling the virus. One is to invent new medicines: ideally a cure or an effective vaccine. The other is to reach more people with existing technology. Both approaches—in the lab and on the ground—are being pursued in tandem by governments, private companies, donors and <small>ngo</small>s.</p><p class="css-1hno3qs e190yofl0" data-component="paragraph">A cure seems a long way off. A vaccine may be closer, but <small>HIV</small> is an elusive target. It is highly mutable, and hides its <small>DNA</small> inside some of the immune cells that are supposed to destroy it. Nina Russell of the Gates Foundation, who has worked on <small>HIV</small> vaccines for “many, many, many, many” years, is nonetheless hopeful.</p><p class="css-1hno3qs e190yofl0" data-component="paragraph">Past failures have taught scientists that they need to design vaccines that can teach the body to make antibodies to tackle a wide range of viral strains. They might have to create three, four or five different vaccines and jab people with all of them, in the correct order. Firms such as Moderna and BioNTech are using m<small>RNA</small> technology to speed up the process. However, even optimists do not expect success this decade. So hitting the 2030 target will depend largely on two things. First, finding and treating more infected people. Second, identifying those who are at risk of infection, and helping them avoid it.</p><div class="css-1bzwzkr eitqf4z1"><figure class="css-qts40t e1197rjj0"><img alt="" data-nimg="1" decoding="async" height="662" loading="lazy" sizes="300px" src="https://www.economist.com/cdn-cgi/image/width=1424,quality=80,format=auto/content-assets/images/20230923_MAC622.png" srcset="https://www.economist.com/cdn-cgi/image/width=16,quality=80,format=auto/content-assets/images/20230923_MAC622.png 16w, https://www.economist.com/cdn-cgi/image/width=32,quality=80,format=auto/content-assets/images/20230923_MAC622.png 32w, https://www.economist.com/cdn-cgi/image/width=48,quality=80,format=auto/content-assets/images/20230923_MAC622.png 48w, https://www.economist.com/cdn-cgi/image/width=64,quality=80,format=auto/content-assets/images/20230923_MAC622.png 64w, https://www.economist.com/cdn-cgi/image/width=96,quality=80,format=auto/content-assets/images/20230923_MAC622.png 96w, https://www.economist.com/cdn-cgi/image/width=128,quality=80,format=auto/content-assets/images/20230923_MAC622.png 128w, https://www.economist.com/cdn-cgi/image/width=256,quality=80,format=auto/content-assets/images/20230923_MAC622.png 256w, https://www.economist.com/cdn-cgi/image/width=360,quality=80,format=auto/content-assets/images/20230923_MAC622.png 360w, https://www.economist.com/cdn-cgi/image/width=384,quality=80,format=auto/content-assets/images/20230923_MAC622.png 384w, https://www.economist.com/cdn-cgi/image/width=480,quality=80,format=auto/content-assets/images/20230923_MAC622.png 480w, https://www.economist.com/cdn-cgi/image/width=600,quality=80,format=auto/content-assets/images/20230923_MAC622.png 600w, https://www.economist.com/cdn-cgi/image/width=834,quality=80,format=auto/content-assets/images/20230923_MAC622.png 834w, https://www.economist.com/cdn-cgi/image/width=960,quality=80,format=auto/content-assets/images/20230923_MAC622.png 960w, https://www.economist.com/cdn-cgi/image/width=1096,quality=80,format=auto/content-assets/images/20230923_MAC622.png 1096w, https://www.economist.com/cdn-cgi/image/width=1280,quality=80,format=auto/content-assets/images/20230923_MAC622.png 1280w, https://www.economist.com/cdn-cgi/image/width=1424,quality=80,format=auto/content-assets/images/20230923_MAC622.png 1424w" style="color:transparent" width="608"/><figcaption class="css-18w36g1 edweubf2"><span class="css-6pzdis edweubf1">image: The Economist</span></figcaption></figure></div><p class="css-1hno3qs e190yofl0" data-component="paragraph"><small>UNAIDS</small> urges countries to aim for “95-95-95”: where 95% of those who have the virus know they have it, 95% of those who know they have it are receiving treatment, and crucially that 95% of those in treatment are “virally suppressed”. If the drugs suppress the virus to a level where it is undetectable—and keep it there—it cannot be passed on sexually.</p><p class="css-1hno3qs e190yofl0" data-component="paragraph">If the world were to reach 95-95-95, the disease would be brought under control, <small>UNAIDS</small> reckons, though tens of millions would still be living with it. In 2022 the figures were 86-76-71, a hefty improvement on 71-48-40 in 2015. But the “last mile” will be hard. “You have to be much more creative,” says Dr Quarraisha Abdool Karim of <small>CAPRISA</small>, a research centre in Durban.</p><p class="css-1hno3qs e190yofl0" data-component="paragraph">One enormous, tricky group is men. They are less likely to get tested than women, not least because they do not get pregnant. Prenatal clinics are a wonderfully convenient place to test women who have recently had unprotected sex. If they test positive, many countries now offer them free drugs, which protect mother, child and future romantic partners.</p><div class="adComponent_advert__V79Pp adComponent_incontent__Bxd2J adComponent_hidden___o_ZB css-0 e1cbnkh80"><div><div class="adComponent_adcontainer__dO1Zm" id="econ-3"></div></div></div><p class="css-1hno3qs e190yofl0" data-component="paragraph">There is no male equivalent of a prenatal clinic. Also, some men have a macho reluctance to seek medical help. They “get very sick before they get tested”, says Sibongile Tshabalala, the chair of the Treatment Action Campaign, an <small>NGO</small> in South Africa.</p><p class="css-1hno3qs e190yofl0" data-component="paragraph">“As men, we’re embarrassed to go to a clinic. We’re taught we need to be strong, so we cannot be seen to be sick,” says Ronnie Sibisi, a 60-year-old from Vosloorus, a township near Johannesburg. He was “a player” with many girlfriends, he says. He knew how the virus was transmitted, but seldom used condoms. “I didn’t think about it,” he shrugs. He did not get tested until he collapsed and woke up in hospital.</p><p class="css-1hno3qs e190yofl0" data-component="paragraph">It is, perhaps, most crucial to reach young women and girls. In sub-Saharan Africa <small>HIV</small> is three times more common among females aged 15-24 than among their male peers. This is because older men often seek younger partners. There is peer pressure on young women to have trendy clothes and hairstyles, says Ms Tshabalala. These cost money, which impels some girls to sleep with older men. And only 36% of young women in eastern and southern Africa report having used a condom the last time they had sex with a casual partner. In West Africa it is only 25%.</p><p class="css-1hno3qs e190yofl0" data-component="paragraph">If their “sugar daddies” infect them, the girls may pass the virus to a partner of their own age. This is the most common way that <small>HIV</small> passes from one age cohort to the next. Breaking that link would allow the younger cohort, who are largely virus-free before they become sexually active, to stay that way. “If you can reduce [new infections among] young girls, you break the back of the pandemic in Africa,” says Dr Salim Abdool Karim, an epidemiologist (who is married to Quarraisha Abdool Karim).</p><p class="css-1hno3qs e190yofl0" data-component="paragraph">A tangle of social problems makes everything harder. Poverty is one. If you are poor, getting tested can be a challenge even if the test is free. A day off work and a bus fare to the clinic can scupper your budget. </p><p class="css-1hno3qs e190yofl0" data-component="paragraph">Male violence is another obstacle. A study in six African countries found that women who had been physically abused in the previous year were 3.2 times more likely to have been infected with <small>HIV</small> recently. Women who live in fear may find it harder to say no to unprotected sex. And the first wave of <small>AIDS</small>, by killing so many parents, made families in some countries even poorer and more unstable than they already were. In South Africa, for example, thanks to a long tradition of migrant labour under apartheid and the recent ravages of <small>AIDS</small>, only a third of children live with both biological parents.</p><p class="css-1hno3qs e190yofl0" data-component="paragraph">Social dysfunction helps the virus spread. Thulina Moukangwe was raped by four different relatives, starting when she was 11. She does not know which one infected her. She did not get tested until she was 17, “because I was young and ignorant”, she says. She received little support from her chaotic family, and did not seek treatment for another five years.</p><p class="css-1hno3qs e190yofl0" data-component="paragraph">Fear of death can make bad boyfriends behave even worse. After Makhosazana Molotsane tested positive her partner was furious. For years he refused to get tested himself, drunkenly sang in the street that she was bringing disease into his home, and burned the condoms Ms Molotsane wanted to use. He seized her antiretroviral drugs and tossed them away. She hid her pills in a nappy bag. He beat her up; eventually she left him.</p><p class="css-1hno3qs e190yofl0" data-component="paragraph">Both women’s fortunes eventually improved. Ms Molotsane, who is 40, found a more supportive partner, who reminds her to take her drugs. Her viral load is low enough that her doctor tells her it is safe for them to have a baby. Ms Moukangwe, who is now 29, has become a “peer educator”: a volunteer who helps people make informed decisions about their health. </p><p class="css-1hno3qs e190yofl0" data-component="paragraph">This is one area where <small>NGO</small>s are especially useful. Health services are overstretched, and people often resist instructions from officials. A more effective way to persuade scared, reluctant people to take the right medicine is for them to talk to people from similar backgrounds. Ms Moukangwe, who had heard that antiretroviral drugs “made you crazy”, started taking them after she saw that a friendly volunteer, who had been taking them for years, was sane and healthy. “You can’t just tell people to go to a clinic,” says Ms Moukangwe. “I talk about myself, as a way of encouraging others.”</p><style data-emotion="css 8p8dhl">.css-8p8dhl{font-family:var(--ds-type-system-serif);font-size:var(--ds-type-scale-2);line-height:var(--ds-type-leading-lower);font-weight:700;color:var(--ds-color-london-5);}</style><h2 class="css-8p8dhl e8f47sz0">Testing, testing</h2><p class="css-1hno3qs e190yofl0" data-component="paragraph">Private companies pitch in, too. Mining firms in southern Africa saw <small>AIDS</small> as a huge threat two decades ago. Their workers were often migrants, who lived far from their families in hostels surrounded by prostitutes. Companies such as Anglo American started offering staff free testing and antiretroviral drugs even as South Africa’s president at the time, Thabo Mbeki, publicly questioned their efficacy. It was a delicate task, recalls Brian Brink, who used to run Anglo’s <small>AIDS</small> programme. Unions had to be convinced that tests would not be used to identify sick staff and fire them.</p><p class="css-1hno3qs e190yofl0" data-component="paragraph">Stigma lingers even in countries where nearly everyone knows someone with <small>hiv</small>. People worry that if they get tested near home, or pick up antiretrovirals from a pharmacy, a neighbour will spot them, says Mr Mdletshe. This makes it less likely that they will get tested in the first place, or stick to a lifelong drug regimen.</p><p class="css-1hno3qs e190yofl0" data-component="paragraph">Sometimes stigma is compounded by law. Some 168 governments criminalise aspects of sex work. This deters sex workers from seeking help. Nokwanda Gambushe, an activist in Durban, complains that cops search sex workers’ handbags and, if they find condoms, arrest them. This hardly encourages safe sex.</p><div class="adComponent_advert__V79Pp adComponent_incontent__Bxd2J adComponent_hidden___o_ZB css-0 e1cbnkh80"><div><div class="adComponent_adcontainer__dO1Zm" id="econ-4"></div></div></div><p class="css-1hno3qs e190yofl0" data-component="paragraph">In addition, 145 countries criminalise drug use and 67 criminalise gay sex. The sharp increase in infections in Eastern Europe and the Middle East is largely due to a lack of prevention services for marginalised populations, reckons <small>UNAIDS</small>. Uganda introduced the death penalty this year for “aggravated homosexuality”, which might make gay Ugandans think twice before walking into a clinic to get tested.</p><p class="css-1hno3qs e190yofl0" data-component="paragraph">Policy can make a huge difference. President Mbeki’s <small>AIDS</small> denialism cost an estimated 300,000 South African lives. However, when he was sacked by his party in 2008, experts persuaded a caretaker government to adopt a first-rate <small>AIDS</small> policy. Drugs were swiftly rolled out, and between 2009 and 2012 the proportion of children under five in South Africa who were orphans plunged from 12% to 7.3%.</p><p class="css-1hno3qs e190yofl0" data-component="paragraph">The best foundation for fighting <small>AIDS</small> is a well-functioning public health system with short queues and sensitive staff, says Mr Mdletshe. Many countries fall short. Waiting times are often long, pharmacies run out of pills, staff are sometimes judgmental. When Ms Moukangwe tested positive, a nurse shouted at her for her lax morals. Even in rich countries, governments that fail to prioritise the disease tend to deal with it badly. The proportion of infected people taking antiretroviral drugs is actually lower in Eastern Europe and central Asia than in sub-Saharan Africa.</p><p class="css-1hno3qs e190yofl0" data-component="paragraph">Governments do not work in a vacuum. The places that have come closest to hitting the 95-95-95 targets are typically African countries where donors are pouring in resources and expertise, such as Botswana, Rwanda, Tanzania and Zimbabwe. The second tier are often rich countries with generous public services (Denmark, Saudi Arabia) or places that developed a serious anti-<small>AIDS</small> strategy early on in the pandemic, such as Cambodia and Thailand.</p><p class="css-1hno3qs e190yofl0" data-component="paragraph">One of the biggest obstacles to curbing the spread of <small>HIV</small> is that the symptoms take a long time to appear. “Recently infected people have high viral loads, and are more likely to infect others. The problem is that those who have been infected don’t yet know it,” laments Dr Salim Abdool Karim. “The gap between being infected and being tested is usually years.”</p><p class="css-1hno3qs e190yofl0" data-component="paragraph">So he suggests something radical: offering <small>P</small>r<small>EP</small> to girls in schools. Instead of waiting for those who think they are at risk to come to a clinic, health workers should go to schools and offer <small>P</small>r<small>EP</small> to all the girls above a certain age, along with testing, contraception and other healthcare services. This could meet stiff resistance from traditionalists who think it would encourage promiscuity. Also, “[it] is only feasible if you have a <small>P</small>r<small>EP</small> that lasts six months,” says Dr Salim Abdool Karim. “You can’t keep going to the schools more than…once every six months. It’s not practical.”</p><p class="css-1hno3qs e190yofl0" data-component="paragraph">Longer-lasting drugs are in the pipeline, and could “change the trajectory” of the disease, says Deborah Waterhouse, the boss of Viiv. The first not-for-profit delivery of Viiv’s two-month injection, to <small>PEPFAR</small>, will be in October. It has regulatory approval in four southern African countries, and has been licensed to cheap generic manufacturers. Gilead, an American firm, has a drug called lenacapavir, which is already used as a treatment, and which breaks down so slowly that it might work as a prophylaxis for six months. It is in clinical trials among girls in South Africa and Uganda.</p><p class="css-1hno3qs e190yofl0" data-component="paragraph">Rolling out new drugs would cost a lot. Roughly $21bn was spent on fighting <small>HIV</small> in poor and middle-income countries in 2022, with slightly less than half coming from donors; <small>UNAIDS</small> thinks $29bn will be needed in 2025. To those who would penny-pinch, Mr Sands retorts that it is “rational to hit this thing hard and fast”. Fighting <small>AIDS</small> slowly would be “much more expensive…If you don’t reduce the number of new infections, every new infection is translating into a lifetime of antiretroviral treatments...and complications.”</p><p class="css-1hno3qs e190yofl0" data-component="paragraph">A lifetime of treating someone with <small>HIV</small> in a poor country costs around $5,000, by one estimate; in rich countries, it is $380,000. By comparison, the cost of averting an infection in Zambia or South Africa is $2,000-$3,000, according to a different study published in the <i>Lancet</i> in 2021. And so long as the virus is circulating somewhere, nowhere is safe. <span class="ufinish">■</span></p></div></section><style data-emotion="css opzdk5">.css-opzdk5{margin:0.875rem 0;}.css-opzdk5 .e1tbpewm0+*{margin-top:0.875rem;}</style><style data-emotion="css umhlpb">.css-umhlpb{margin-top:0.875rem;}.css-umhlpb +.eq1asik0{margin-top:4rem;padding-bottom:0;}</style></div></div><style data-emotion="css j50zk1">.css-j50zk1{position:relative;display:none;}@media (min-width: 80rem){.css-j50zk1{grid-column-start:9;}}@media (min-width: 89rem){.css-j50zk1{grid-column-start:13;}}@media (min-width: 80rem){.css-j50zk1{grid-column-end:13;}}@media (min-width: 89rem){.css-j50zk1{grid-column-end:17;}}@media (min-width: 80rem){.css-j50zk1{grid-row-start:1;}}@media (min-width: 80rem){.css-j50zk1{grid-row-end:span 4;}}@media (min-width: 80rem){.css-j50zk1{display:block;}}.css-j50zk1:last-child::after{height:0;}</style><div class="css-j50zk1 e1mdktgm0" data-test-id="right-hand-rail-ads"><style data-emotion="css 1y1zooy">.css-1y1zooy{display:inline;}.css-1y1zooy >*+*{margin-top:2rem;}.css-1y1zooy >*:only-child{margin-top:1.25rem;}.css-1y1zooy >*:last-child{position:-webkit-sticky;position:sticky;top:1.5rem;}</style><div class="css-1y1zooy epfkve70"><div class="adComponent_advert__V79Pp adComponent_right__o9T6r adComponent_hidden___o_ZB"><div><div class="adComponent_adcontainer__dO1Zm" id="econright-r0"></div></div></div><div class="adComponent_advert__V79Pp adComponent_right__o9T6r adComponent_hidden___o_ZB"><div><div class="adComponent_adcontainer__dO1Zm" id="econright-r1"></div></div></div></div></div></div><style data-emotion="css mqgbir">.css-mqgbir{margin-top:6rem;}.css-mqgbir .ds-section-headline{margin-bottom:1rem;}</style></div></article></main></div></div><div id="piano-ribbon"></div></div></div></div>
</div></body></html>